Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in head and neck squamous cell carcinoma (HNSCC)

KEYTRUDA® (pembrolizumab) KEYNOTE-048 5-year follow-up data

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) KEYNOTE-048 clinical data presentation

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® monotherapy

KEYTRUDA mode of action

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Patient management

A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

PD-L1 testing and CPS interpretation in HNSCC

Early PD-L1 testing for M/uR HNSCC

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

More information about KEYTRUDA® (pembrolizumab) in HNSCC

By clicking this link you will be taken to an MSD promotional website.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.